Status:
COMPLETED
Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer
Lead Sponsor:
Yonsei University
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
This study will evaluate the efficacy and safety profile, response rate, progression free survival, overall survival of bevacizumab (Avastin) added to chemotherapy in patients with epithelial ovarian ...
Eligibility Criteria
Inclusion
- Patients who have histologically or cytologically confirmed recurrent epithelial ovarian cancer, fallopian tube cancer, or peritoneal cancer.
- Patients who have platinum-resistant disease (defined as having relapsed within 6 months of her last platinum-containing regimen)
- Patients who have underwent chemotherapy of either weekly paclitaxel + bevacizumab, topotecan + bevacizumab, pegylated liposomal doxorubicin + bevacizumab in 2nd line or 3rd line chemotherapy.
Exclusion
- Patients with previous treatment with bevacizumab.
- Patients who received bevacizumab combination therapy in 4th line or more chemotherapy.
Key Trial Info
Start Date :
September 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2018
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03367182
Start Date
September 1 2017
End Date
January 31 2018
Last Update
January 11 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Severance hospital
Seoul, South Korea, 03722